Nexthera Capital’s CytomX Therapeutics CTMX Stock Holding History

Nexthera Capital’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-179,870	Closed	-$3.8M	–	47
2017 Q4	$3.8M	Buy	+179,870	New	+$3.73M	0.7%	32

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nexthera Capital's CTMX Position: Q1 2018 in Review

Nexthera Capital sold out of CytomX Therapeutics (CTMX) in Q1 2018, closing a stake of 179,870 shares — an estimated $3.8M sold.

Nexthera Capital first reported a position in CTMX in Q4 2017 and held it in 1 quarter. The position peaked at $3.8M in Q4 2017. 141 funds tracked by Wall St. Rank hold CTMX as of Q1 2018.

Nexthera Capital reported no remaining CytomX Therapeutics position as of Q1 2018 after selling out during the quarter.
Nexthera Capital sold 179,870 CytomX Therapeutics shares in Q1 2018, an estimated $3.8M.
Nexthera Capital first reported a position in CytomX Therapeutics in Q4 2017 and held it in 1 quarter.
Nexthera Capital's CytomX Therapeutics position peaked at $3.8M in Q4 2017.
141 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2018.

Based on Nexthera Capital's 13F filing for Q1 2018, filed 15 May 2018.